TABLE 1.

List of some of active and on-going clinical trials using surfactant compounds as a therapeutic agent against RDS/ARDS (Subramaniam et al., 2020).

S. No.	Study	Disease	Intervention	Description	Study size	Country	Status	Year
1	Surfactant for neonate with acute respiratory distress syndrome (ARDS)	ARDS	Surfactant	Surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS	200	China	Recruiting	2017 Till date
2	Surfactant administration via thin catheter using a specially adapted video laryngoscope	RDS	Curosurf	Surfactant administration via thin catheter using a specially adapted VN scope	20	Israel	Active, not recruiting	2020 Till date
3	Aerosolized surfactant in neonatal RDS	RDS	Surfactant	Dose: 100 mg phospholipid/kg and 200 mg phospholipid/kg	159	United States	Completed, not recruiting	2021 Till date
4	Surfactant via endotracheal tube vs. laryngeal Mask airway (LMA) in preterm neonates with respiratory distress syndrome	RDS	Remifentanil	Additional premedication in the endotracheal intubation/INSURE arm	130	United States	Recruiting	2019 Till date
5	The effect of surfactant dose on outcomes in preterm infants with RDS	RDS	Surfactant	Two doses: 100–130 and 170–200 mg/kg; repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 h, up to maximum of two additional doses when indicated	2,600	United Kingdom	Recruiting	2019- Till date
6	Curosurf in adult acute respiratory distress syndrome due to COVID-19	COVID-19 ARDS	Poractant alfa	-	20	France	Recruiting	2020 Till date

RDS, Respiratory Distress Syndrome; ARDS, Acute Respiratory Distress Syndrome.